| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| SF | Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f... |
| IF | Impact Factor |
|---|---|
| A.I.M.S. | Arthritis Impact Measurement Scale |
| AIMS2 | Arthritis Impact Measurement Scale |
| CCI | Controlled cortical impact |
| EI | Electron Impact |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| sickness impact profile | A quality-of-life scale developed in the united states in 1972 as a measure of health status or dysfunction generated by a disease. It is a behaviourally based questionnaire for patients and addresses activities such as sleep and rest, mobility, recreation, home management, emotional behaviour, social interaction, and the like. It measures the patient's perceived health status and is sensitive enough to detect changes or differences in health status occurring over time or between groups. (12 Dec 1998) |
|---|---|
| draft environmental impact statement | (DEIS) A draft statement of environmental effects. Section 102 of the National Environmental Policy Act requires a DEIS for all major federal actions. The DEIS is released to the public and other agencies for comment and review. (05 Dec 1998) |
| impact | 1. Contact or impression by touch; collision; forcible contact; force communicated. "The quarrel, by that impact driven." (Southey) 2. <mechanics> The single instantaneous stroke of a body in motion against another either in motion or at rest. Source: Websters Dictionary (01 Mar 1998) |
| impact fusion | <radiobiology> Fusion approach where a fuel projectile is acclerated and impacted into either a stationary target or another projectile. This is valuable for scientific purposes but not a candidate for a fusion energy source because the likelihood of fusion occurring in a single collision is too low. Multiple accelerated pellets colliding with spherical symmetry might be a viable inertial confinement approach. An impact fusion driver accelerates the macroparticles and is used in inertial confinement fusion. (13 Nov 1997) |
| impact resistance | The ability of a lens for eyewear to withstand impact without shattering or breaking, i.e., of a 3/8 -inch steel ball dropped 50 feet; criteria for determination of impact resistance are specified by U.S. Regulations. (05 Mar 2000) |
| environmental impact statement | (EIS; FEIS) A statement of the environmental effects of a proposed action and of alternative actions. Section 102 of the National Environmental Policy Act (NEPA) requires an EIS for all major federal actions. (05 Dec 1998) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
| adrenal weight factor | A postulated substance of adenohypophysial origin responsible for maintenance of the weight of the adrenal cortex. (05 Mar 2000) |
| adrenocorticotropic releasing factor | Hormone produced by hypothalamus that causes pituitary to secrete adrenocorticotropic hormone. (05 Mar 2000) |
| a-factor | <molecular biology> A protein which is found in the bacterial genus Streptomyces that helps start the production of streptomycin and the process of morphological differentiation. It is used in biotechnology to induce these functions in mutant strains of Streptomyces that cannot produce it themselves. (09 Feb 1998) |
| angiogenesis factor | Substance causing proliferation of new blood vessels. It is found in tissues with high metabolic requirements, such as the retina, and in certain cancers. The factor is also released by hypoxic macrophages at the edges or outer surfaces of wounds and initiates revascularization in wound healing. (12 Dec 1998) |
| animal protein factor | <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism. (27 Sep 1997) |
| antialopecia factor | A member of the vitamin B complex necessary for growth of yeast and of mice, absence from the diet causes hair loss and dermatitis in mice. (27 Sep 1997) |
| antianaemic factor | <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism. (27 Sep 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|